http://localhost:8080/xmlui/handle/123456789/7246 Sat, 18 Apr 2026 08:54:21 GMT 2026-04-18T08:54:21Z http://localhost:8080/xmlui/handle/123456789/7259 Development and evaluation of gastro retentive controlledrelease dosage form of chlordiazepoxide Amin, Roshani Purpose: The aim of present study was to develop and evaluate gastro retentive controlled release dosage form of Chlordiazepoxide by using HydroxyPropylMethylCellulose K 4 M and Xanthum gum to avoid accumulation of metabolites of Chlordiazepoxide and to reduce dosing frequency. Hydrodynamically balanced system was evaluated for this purpose. Method: Tablets were prepared successfully by wet granulation method by using PVP K 30 as binding agent and HPMC K4M, Xanthum gum as retarding polymer. Optimization of formulation was done by using 32 full factorial design where independent variables are X1 (concentration of HPMC K4M ) and X2 (concentration of Xanthum gum).The prepare blend of tablet were evaluated for pre - compression parameters like bulk density, tapped density, carr’s index, hausner’ ratio and in vitro drug release, % swelling index and stability study. Result: The prepared blend has good flow property and compressibility. Due to combination of HPMC K4M and Xanthum gum polymers tablets maintain its matrix integrity and show good prolonged release in controlled manner. Swelling index was in range from 33 to 75 %. In vitro drug release of tablet was carried in 0.1N HCL up to 18 hrs and its show 95-98 % drug release. Conclusion: Use of Xanthum gum control the initial burst drug release effect of matrix tablet and HPMC is rapidly swelling hydrophilic polymer which form highly viscous gel barrier which control the drug release from system. For Full Thesis Kindly contact to respective Library Sat, 01 Apr 2017 00:00:00 GMT http://localhost:8080/xmlui/handle/123456789/7259 2017-04-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/7258 Bioresponsive proliposomes based dry powder of anti-neoplastic agent for lung cancer targeting SHARMA, MUKESHKUMAR The aim of the present investigation was to develop and evaluate bioresponsive proliposomes based dry powder of docetaxel using spray drying technique. Docetaxel can improve the cancerous condition if given in the form of bioresponsive proliposomes as dry powder inhaler(DPI) dosage form. Bioresponsive proliposomes based dry powder of docetaxel was evaluated for particle size, percent drug entrapment, flow property, zeta potential, surface morphology, aerosol performance, in-vitro drug release study and stability study. Optimization of process parameter were done by Box Behnken Design (BBD) using Design Expert software. FTIR study shows that neither drug decomposition nor drug-excipients and excipient-excipient interactions occurred in the formulation. Analytical method was performed using HPLC. Bioresponsive proliposomes based dry powder was successfully prepared using Docetaxel (7%w/w), HSPC (82%w/w), cholesterol (10%w/w), Dextran-b-poly(l-histidine)(5%w/w), Elastin (3%w/w), Respitose SV001 (15%w/w), Magnesium stearate (0.5%w/w). Optimization study of process parameter shows that batch prepared with inlet temperature 90°C, aspiratory rate 45 Nm3/hr, feed flow rate 2 ml/min considered as optimum condition for spray drying. Particle size, zeta potential, and percent drug entrapment were found to be 2.56 ± 0.09 μm, -19.0 ± 0.1 mV and 65.71 ± 0.12%. Scanning electron microscopy study indicates that the particles were found to be in spherical shape. Carr’s index, hausner’s ratio and angle of repose were found to be 14.65 ± 0.18%, 1.17 ± 0.01 and 28.33 ± 0.11° respectively which show good flow property of bioresponsive proliposomes based dry powder. In-vitro drug release of optimized batch was found to be 97.25 ± 0.27 % up to 24 hr. Fine Particle Fraction (FPF), Fine Particle Dose (FPD), Geometric Standard Deviation (GSD) and Mass Median Aerodynamic Diameter (MMAD) were found to be 14.96, 1.42mg, 1.62 and 2.85 μm respectively for optimized batch. Stability study shows Docetaxel loaded bioresponsive proliposomes based dry powder was stable at accelerated condition. The present study demonstrated that, a bioresponsive proliposomes based dry powder inhalation system is suitable for respiratory deposition and hold great potential for deep lung targeting. For Full Thesis Kindly contact to respective Library Mon, 01 May 2017 00:00:00 GMT http://localhost:8080/xmlui/handle/123456789/7258 2017-05-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/7253 Formulation and evaluation of mucoadhesive vaginal tablet of clindamycin phosphate KANOJIA, DIXITABEN Problem statement: The bacterial vaginosis most frequently occur in women of reproductive age group or childbearing age group. In which problems are occur like early or late miscarriage, preterm labour, preterm delivery, preterm labour rapture of membrane, low birth weight and Increase efficiency of HIV. For bacterial vaginosis conventional dosage form are available which have problem like leakage, messiness and short residence time. Purpose: The main purpose of this study was to formulate mucoadhesive intravaginal tablet of clindamycin phosphate. It was developed to achieve good therapeutic effect and patient compliance in the treatment of bacterial vaginosis. The formulation has sustain release effect with good mucoadhesion due to mucoadhesive polymer so that ultimately decrease dose frequency. Method: The mucoadhesive vaginal tablets were prepared by direct compression method. FTIR had employed to study drug excipient incompatibility. Analytical method was developed using HPLC. Optimization of formulation was done by 32 full factorial design using DOE. Result: Mucoadhesive vaginal tablets were evaluated for % swelling index, Mucoadhesin strength, drug content, in-vitro % drug release, ex-vivo mucoadhesion time. The ex-vivo mucoadhesion time of optimized batch F3 upto 9 hr, 99.25 % drug content, 88.34% drug release at 8 hr were obsereved. Stability study shows developed mucoadhesive intravaginal tablet was stable at 30°C ± 2°C at 65 ± 5% RH and 40°C ± 2°C at 75 ± 5% RH condition after three months. Conclusions: From the results it was concluded that the mcoadhesive vaginal tablet had maximum drug release in 8 hr, good mcoadhesion time as well as good stability. This study proves optimized vaginal formulation of clindamycin phosphate is potential against bacterial vaginosis. For Full Thesis Kindly contact to respective Library Mon, 01 May 2017 00:00:00 GMT http://localhost:8080/xmlui/handle/123456789/7253 2017-05-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/7251 Preparation and ex-vivo evaluation of clindamycin phosphate dental films for periodontitis PANDYA, DHRUTIKABEN Problem statement: Periodontitis is a inflammatory gum disease. It can affect one or more of the periodontal tissues/structures (e.g. alveolar bone, periodontal ligament, cementum and gingiva). The common symptoms of periodontitis include redness and bleeding of gums while brushing teeth, gum swelling, splitting out blood after brushing the teeth, lose teeth in last stage, halitosis or bad breath, gingival recession, resulting in apparent lengthening of teeth, deep pockets formation between teeth and gum. The proportion of the population above the age of 15 years with this disease could be 80–90%. Periodontitis associated with diabetes, chronic obstructive pulmonary disease, Atherosclerosis, Kidney disease. Purpose: The objective of this study was to resolve the problems arise in different dosage forms which are given by systemic root. Topical site specific delivery of clindamycin phosphate would reduce the side effect occurs by systemic drug delivery like hypersensitivity, gastrointestinal intolerance and bacterial resistance. Clindamycin phosphate has 60% susceptibility against oral pathogens. Periodontal film having potential to deliver small amount of drug with prolong action. Methods: The site specific dental films of clindamycin phosphate was formulated by solvent casting method using ethyl cellulose as a polymer, Eudragit RL 100 as a copolymer, Dichloromethane: Methanol (1:1) as a solvent and Dibutyl phthalate as a plasticizer. The films were evaluated for thickness uniformity, folding endurance, weight uniformity, surface pH, Surface morphological study with Scanning electron microscopy, In-situ antibacterial study, In-vitro drug release study, Ex-vivo and In- vitro antibacterial study, comparison study with marketed formulation and kinetic model study and Gas chromatography study for the measurement of residual solvent amount. Results: The best film was selected as a one which is prepared by ethyl cellulose and eudragit RL 100 is C8 since, give maximum drug release with 77.26% which is above the Minimum inhibitory concentration. The formulation follows the krosmeyer peppas model and release was done via fickian diffusion mechanism. The Concentration of drug was found to be 75% from the in-situ release study. In-vitro antibacterial study shows that the the formulated polymeric films of clindamycin phosphate have a similar activity as compare to standard drug sample. Ex-vivo antibacterial study shows better activity against standard drug sample. In compare to marketed formulation (Chlorhexidine Mouth- wash) Fabricated Clindamycin Phosphate containing films have better antibacterial activity. The surface morphological study by scanning electron microscopy shows that the drug molecules are uniformly distributed with polymers in the formulation. The amount of residual solvent was found to be 221ppm in the formulation by gas chromatography study. Conclusions: Ethyl cellulose - eudragit Rl 100 combination is the batter carrier among the others for the preparation of Clindamycin phosphate dental films for prolonging the drug action up to 6 days. For Full Thesis Kindly contact to respective Library Mon, 01 May 2017 00:00:00 GMT http://localhost:8080/xmlui/handle/123456789/7251 2017-05-01T00:00:00Z